COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance

Bermas, Bonnie L.; Gianfrancesco, Milena; Tanner, Helen; Seet, Andrea M; Aguiar, Mathia Cecilia; Al-Adhoubi, Nasra K.; Emadi, Samar Al; Cunha, Bernardo Matos da; Flood, Rachael; Kusevich, D.; McCarthy, Eoghan; Patel, Naomi J; Ruderman, Eric; Sattui, Sebastian E.; Sciascia, Savino; Siddique, Faizah; Valenzuela‐Almada, Maria O; Wise, Leanna; Worthing, Angus B; Zell, JoAnn; Bhana, Suleman; Costello, Wendy; Duarte‐García, Alí; Grainger, Rebecca; Gossec, Laure; Hausmann, Jonathan S; Hyrich, Kimme L; Lawson‐Tovey, Saskia; Liew, Jean W; Sirotich, Emily; Sufka, Paul; Wallace, Zachary S; Machado, Pedro; Strangfeld, Anja; Clowse, Megan E.B.; Yazdany, Jinoos; Robinson, Philip C

doi:10.3899/jrheum.210480

Cited by 10 publications

(7 citation statements)

References 13 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fever and cough were the predominant symptoms in our pregnant patients, and only a minority needed hospitalization. A similar finding was observed in data from the Global COVID-19 Registry, where only 5% of pregnant women with autoimmune rheumatic diseases required hospitalization with supplemental oxygen, and all eventually recovered [ 6 ].…”

Section: Discussionsupporting

confidence: 81%

“…This information may be subject to recall bias and needs to be explored in further studies. The rates of caesarean section and prematurity were similar to the data reported by the COVID-19 Global Registry Alliance (GRA) [ 6 ].…”

Section: Discussionsupporting

confidence: 79%

“…Only 10 pregnant women needed hospitalisation, and all recovered from the infection. They also reported favourable pregnancy outcomes with 16/22 term births, one miscarriage, and one termination at nine weeks [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic in Qatar

Satti¹,

Østensen²,

darrgham³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

Objective: Pregnant women with autoimmune rheumatic diseases are considered to have a high risk of obstetric complications with the emergence of the Coronavirus disease (COVID-19) pandemic. Therefore, we aimed to assess the impact of COVID-19 on this high-risk group. Methods: This cross-sectional cohort study (March to December 2020) was conducted at the largest tertiary center in Qatar (Hamad Medical Corporation). Eighty consecutive patients following up at the center during pregnancy were surveyed through telephonic interviews. Data on COVID-19 and pregnancy outcomes were extracted from electronic hospital records. Results:Eighty pregnant women with autoimmune rheumatic diseases were included. Among them, 17 (21.3%) (95% confidence interval [CI]: 12.9-31.8%) were diagnosed with COVID-19, five were hospitalized, and only one required intensive care unit admission. The proportion of adverse obstetric outcomes in the cohort was 29.5% (n = 23; 95% CI: 19.7-40.9%). Prematurity (n = 14; 19.4%) and caesarean section (n = 30; 41.1%) were the most prevalent adverse events. There was no statistical difference in adverse pregnancy outcomes between women with and without COVID-19. Conclusion: COVID-19 did not affect pregnancy outcomes in women with autoimmune rheumatic diseases.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 79%

See 1 more Smart Citation

Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic in Qatar

Satti¹,

Østensen²,

darrgham³

et al. 2022

Cureus

Self Cite

View full text Add to dashboard Cite

show abstract

“…Rituximab is a B cell-depleting therapy (BCDT), and BCDTs are also associated with poor outcomes for COVID-19 in people with conditions other than rheumatic diseases 50 . In the third study, researchers reported generally favourable pregnancy outcomes in 39 women with rheumatic disease who had COVID-19 whilst pregnant 51 . The fourth study contained an analy sis of pooled data from the C19-GRA registry and from international registries for people with COVID-19 and inflammatory bowel disease or skin psoriasis, to examine outcomes for people receiving treatment with TNF inhibitors 52 .…”

Section: Key Pointsmentioning

confidence: 94%

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

et al. 2022

Self Cite

View full text Add to dashboard Cite

The COVID-19 pandemic has brought challenges for people with rheumatic disease in addition to those faced by the general population, including concerns about higher risks of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and poor outcomes of COVID-19. The data that are now available suggest that rheumatic disease is associated with a small additional risk of SARS-CoV-2 infection, and that outcomes of COVID-19 are primarily influenced by comorbidities and particular disease states or treatments. Despite considerable advances in our knowledge of which therapeutic agents provide benefits in COVID-19, and of what constitutes effective vaccination strategies, the specific considerations that apply to people with rheumatic disease are yet to be definitively addressed. An overview of the most important COVID-19 studies to date that relate to people with rheumatic disease can contribute to our understanding of the clinical-care requirements of this population.

show abstract

“…Несмотря на наличие большого числа публикаций о взаимовлиянии COVID-19 и ИВРЗ, COVID-19 и беременности, данных о течении COVID-19 у беременных с ИВРЗ крайне мало. Наиболее интересными представляются материалы Глобального ревматологического альянса COVID-19 (The COVID-19 Global Rheumatology Alliance), созданного в марте 2020 г. для сбора и анализа информации о COVID-19 и ИВРЗ [12]. С 30 июня 2020 г. по 14 января 2021 г. в регистр было включено 39 беременных с ревматоидным артритом (9), системной красной волчанкой (9), антифосфолипидным синдромом (6), АС (3) и по одной беременной с другими ИВРЗ.…”

unclassified

COVID-19 in women with ankylosing spondylitis during pregnancy and within one year after childbirth

Krichevskaya¹,

Дубинина²,

Ильиных³

et al. 2022

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Objective – to describe the course of COVID-19 and its effect on ankylosing spondylitis (AS) activity in women infected with SARS-CoV-2 during pregnancy and within one 1 year after childbirth.Material and methods. 78 pregnant women with confirmed AS (modified New York criteria, 1984) were included for prospective observation. In the course of the COVID-19 pandemic (03.2020 – 04.2022) 26 of them were followed during pregnancy and 22 within maximum 12 months after childbirth. The average age of pregnant patients was 33.0±3.9 years, the duration of the disease was 117.0±72.0 months. The average age of patients after delivery was 31.5±4.3 years. The activity according to the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in the 1st, 2nd and 3rd trimester of pregnancy was 2.0±1.4, 2.0±1.4 and 1.9±1.5. The activity according to BASDAI at 1, 6 and 12 months after delivery was 2.0±1.3, 2.2±1.3 and 2.5±2.0 respectively.Results. 4 women were COVID-positive: 3 of them at the beginning of 3rd trimester, 1 – on the 38th week of pregnancy. In 3 cases, the activity of AS was low, in one – high due to axial manifestations and arthritis. In 3 women, the course of COVID-19 was mild, in one – moderate (febrile temperature for more than 3 days); only 1 woman had a dry cough. One pregnant woman canceled AS therapy (certolizumab pegol (CZP)), against which the back pain of the inflammatory rhythm increased. In other cases, AS therapy was not canceled, there was no effect of COVID on AS activity.Within one year after delivery 5 women were COVID-positive. At the time of infection, AS activity in all patients was low, 3 women received CZP. In all cases, COVID proceeded with febrile fever for at least 1 day, while general symptoms disappeared within a maximum of 7 days. Only 1 woman had a dry cough. No effect of COVID on AS activity was found, including in 2 patients who canceled CZP. None of the patients were vaccinated against COVID.Conclusion. According to preliminary data, COVID in pregnant women with AS is to be characterized by a mild to moderate course. During pregnancy, against the background of ongoing therapy, there was no increase in AS activity. During lactation, there was also no effect of COVID on the initially low AS activity. One of the main symptoms of COVID during lactation was a febrile fever, regardless of the period between the childbirth and infection.

show abstract

COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance

Cited by 10 publications

References 13 publications

Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic in Qatar

Characteristics and Obstetric Outcomes in Women With Autoimmune Rheumatic Disease During the COVID-19 Pandemic in Qatar

COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations

COVID-19 in women with ankylosing spondylitis during pregnancy and within one year after childbirth

Contact Info

Product

Resources

About